254 related articles for article (PubMed ID: 20563247)
1. Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.
van Houdt WJ; Hoogwater FJ; de Bruijn MT; Emmink BL; Nijkamp MW; Raats DA; van der Groep P; van Diest P; Borel Rinkes IH; Kranenburg O
Neoplasia; 2010 Jun; 12(6):443-52. PubMed ID: 20563247
[TBL] [Abstract][Full Text] [Related]
2. A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans.
Bongers G; Muniz LR; Pacer ME; Iuga AC; Thirunarayanan N; Slinger E; Smit MJ; Reddy EP; Mayer L; Furtado GC; Harpaz N; Lira SA
Gastroenterology; 2012 Sep; 143(3):730-740. PubMed ID: 22643351
[TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
4. An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells.
Bae JA; Yoon S; Park SY; Lee JH; Hwang JE; Kim H; Seo YW; Cha YJ; Hong SP; Kim H; Chung IJ; Kim KK
Clin Cancer Res; 2014 Aug; 20(15):4115-28. PubMed ID: 24893630
[TBL] [Abstract][Full Text] [Related]
5. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
[TBL] [Abstract][Full Text] [Related]
6. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Derer S; Berger S; Schlaeth M; Schneider-Merck T; Klausz K; Lohse S; Overdijk MB; Dechant M; Kellner C; Nagelmeier I; Scheel AH; Lammerts van Bueren JJ; van de Winkel JG; Parren PW; Peipp M; Valerius T
Neoplasia; 2012 Mar; 14(3):190-205. PubMed ID: 22496619
[TBL] [Abstract][Full Text] [Related]
8. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
10. Network quantification of EGFR signaling unveils potential for targeted combination therapy.
Klinger B; Sieber A; Fritsche-Guenther R; Witzel F; Berry L; Schumacher D; Yan Y; Durek P; Merchant M; Schäfer R; Sers C; Blüthgen N
Mol Syst Biol; 2013; 9():673. PubMed ID: 23752269
[TBL] [Abstract][Full Text] [Related]
11. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract][Full Text] [Related]
13. Kras in metastatic colorectal cancer.
Wicki A; Herrmann R; Christofori G
Swiss Med Wkly; 2010; 140():w13112. PubMed ID: 21104470
[TBL] [Abstract][Full Text] [Related]
14. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
[TBL] [Abstract][Full Text] [Related]
15. EGFR and KRAS in colorectal cancer.
Markman B; Javier Ramos F; Capdevila J; Tabernero J
Adv Clin Chem; 2010; 51():71-119. PubMed ID: 20857619
[TBL] [Abstract][Full Text] [Related]
16. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
Huang Y; Kim SO; Jiang J; Frank SJ
J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
[TBL] [Abstract][Full Text] [Related]
18. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
19. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
[TBL] [Abstract][Full Text] [Related]
20. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.
Stintzing S; Heinemann V; Moosmann N; Hiddemann W; Jung A; Kirchner T
Dtsch Arztebl Int; 2009 Mar; 106(12):202-6. PubMed ID: 19471640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
